<DOC>
	<DOC>NCT02972216</DOC>
	<brief_summary>A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy</brief_summary>
	<brief_title>Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically or cytologically confirmed unresectable locally advanced NSCLC with progressed or recurred after no more than four previous docetaxelfree chemotherapy regimens, or unresectable locally advanced or metastatic SCCHN or recurred after previous docetaxelfree chemotherapy regimens 1. Women who are nursing or pregnant during the study period; 2. Patients with carcinoid tumors, smallcell carcinoma of the lung; 3. A history of another malignancy within the last five years (except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the uterine cervix); 4. Any other morbidity or situation with contraindications for chemotherapy (e.g. active infection, myocardial infarction in the preceding 6 months); 5. Neutrophil counts &lt; 1,500 cells/mm3; 6. A history of hypersensitivity to docetaxel or cisplatin; 7. Symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias; 8. Subjects have active hepatitis; 9. Subjects are known positive for Human Immunodeficiency Virus (HIV); 10. Any condition judged by investigator, participates the study will jeopardize patient's wellbeing</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>